Abstract

BackgroundIt is recognized that the expression of interferon (IFN)-stimulated genes (IFN signature) plays a significant role in several autoimmune diseases (AIDs) [1], such as systemic erythematosus lupus (SLE), idiopathic inflammatory...

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
POS0975 VALIDATION OF INTERFERON STIMULATED GENE SCORES, PREVIOUSLY DEVELOPED IN PERIPHERAL BLOOD MONONUCLEAR CELLS, IN WHOLE BLOOD SAMPLES
M Wilson ... A Burska
Annals of the Rheumatic Diseases | VOL. 82
M Wilson, et. al.M Wilson ... A Burska
30 May 2023
In Search of Magic Bullets: The Golden Age of Immunotherapeutics
Yuka Kanno ... Andrew C Chan
Cell | VOL. 157
Yuka Kanno, et. al.Yuka Kanno ... Andrew C Chan
01 Mar 2014
P11 TLR7 and TLR9 mediated interferon response in incomplete systemic lupus erythematosus
Berber Doornbos-Van Der Meer ... Hendrika Bootsma
Lupus Science & Medicine | VOL. 11
Berber Doornbos-Van Der Meer, et. al.Berber Doornbos-Van Der Meer ... Hendrika Bootsma
01 Mar 2024
Interferon response and profiling of interferon response genes in peripheral blood of vaccine-naive COVID-19 patients.
Paul K S Chan ... Xingyan Wang
Frontiers in immunology | VOL. 14
Paul K S Chan, et. al.Paul K S Chan ... Xingyan Wang
10 Jan 2024
View more papers

More From: Annals of the Rheumatic Diseases

Paper Title
Journal
Date
Author
The associations between poorer pain-related health status and increased hospitalisations and excess mortality in patients with rheumatoid arthritis (RA): a prospective cohort analysis using the Australian Rheumatology Association Database (ARAD)
Huai Leng Pisaniello ... Samuel Lawrance Whittle
Annals of the Rheumatic Diseases | VOL. -
Huai Leng Pisaniello, et. al.Huai Leng Pisaniello ... Samuel Lawrance Whittle
29 May 2024
Integrated safety analysis of filgotinib in patients with moderate-to-severe rheumatoid arthritis over a treatment duration of up to 8.3 years
Gerd R Burmester ... Daniel Aletaha
Annals of the Rheumatic Diseases | VOL. -
Gerd R Burmester, et. al.Gerd R Burmester ... Daniel Aletaha
23 May 2024
BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial
Weijia Wang ... Yong Yuan
Annals of the Rheumatic Diseases | VOL. -
Weijia Wang, et. al.Weijia Wang ... Yong Yuan
22 May 2024
Exploring the effect on primary endpoints in trials testing targeted therapy interventions for rheumatoid arthritis: a meta-epidemiological study on the appropriate use of a core outcome set
Philip Rask Lage-Hansen ... Robin Christensen
Annals of the Rheumatic Diseases | VOL. -
Philip Rask Lage-Hansen, et. al.Philip Rask Lage-Hansen ... Robin Christensen
22 May 2024
View more papers